Highest-materiality recent filing
XBP Q2 revenue $191.3M (-14% YoY), EBITDA $21.9M (+8.4%), raises efficiency target
Revenue $191.3M, down 14.0% YoY pro forma; net loss $16.7M.
XBP Global Q1 revenue down 14.2% to $197.1M, net loss $26.8M; Board launches strategic review
Revenue $197.1M, pro forma decline 14.2% YoY; Net loss $26.8M.
XBP Global Q4 revenue falls 15.1% pro forma; full-year GAAP net income $1.1B on acquisition
Full-year reported revenue $791.0M, down 9.4% YoY; pro forma revenue $879.6M, down 13.6%.
XBP Global amends ABL credit agreement; eliminates $7.5M excess availability covenant
Third Amendment to ABL Credit Agreement dated March 6, 2026 eliminates minimum excess availability of $7.5M.
XBP Global reports Q3 revenue $209.1M, down 10.4% YoY; pro forma EBITDA up 7.4%
As-reported revenue $209.1M, -10.4% YoY; pro forma revenue $220.4M, -18.1%.
XBP Global receives Nasdaq bid-price deficiency notice; 180-day cure period
Company received Nasdaq notice on Sept 16, 2025 due to bid price below $1.00 for 30 consecutive business days (Aug 4 to Sep 15).
XBP Global Q2 revenue up 17.8% YoY, completes BPA acquisition eliminating $1.1B debt
Q2 revenue $39.6M (+17.8% YoY); gross margin 29.8% (+1020 bps); Adj. EBITDA $3.3M (+173.8% YoY).
XBP emerges from restructuring; issues 81.8M shares to noteholders, new board and $150M ABL facility
Issued 81,799,821 shares of common stock to allowed note claims; total outstanding 117,516,255 shares.
XBP Europe completes acquisition of Exela BPA; combined revenue >$900M, eliminates $1.1B debt
Acquisition of Exela Technologies BPA closed, resulting in combined company with over $900M annual revenue and ~11,000 employees across 19 countries.
XBP Europe Q1 revenue $37.7M, Adj EBITDA $3.7M (+25.6% YoY), net loss $3.9M due to stock comp
Revenue $37.7M, down 1.2% YoY but up 5.7% sequentially; gross margin 30.1% (+380 bps YoY).
XBP Europe regains Nasdaq compliance; listing continues on Capital Market
Received notice from Nasdaq Hearings Panel confirming compliance with Listing Rule 5550(b)(2) (minimum $35M market value of listed securities).
XBP Europe FY24 revenue $142.8M (-8% YoY); operating profit up to $3.5M; signs LOI for Exela BPA
Full-year revenue $142.8M, down 8.0% YoY; gross margin improved 110 bps to 26.8%.
XBP Europe Q3 revenue down 5.6% YoY but adjusted EBITDA jumps 116% to $4.8M
Revenue of $35.4M (-5.6% YoY); Bills & Payments $24.6M (-3.1%), Technology $10.8M (-10.8%).
XBP Europe receives Nasdaq delisting determination for MVPHS non-compliance; hearing requested
Nasdaq notified XBP Europe on Oct 18, 2024 that it fails MVPHS ($15M minimum) for continued listing on Nasdaq Global Market.
On Aug 30, 2024, Nasdaq notified XBP that its MVLS was below $50M minimum for 30 consecutive days.
XBP Europe Q2 2024 revenue falls 14.8% to $36.1M; net loss widens to $4.7M
Revenue of $36.1M, down 14.8% YoY; net loss of $4.7M vs $0.6M loss in 2Q 2023.
XBP Europe completes $48M financing with HSBC, including $33M incremental liquidity
New Facilities Agreement with HSBC: Term Loan A (£3M), Term Loan B (€10.5M), Revolving Credit Facility (£12M), plus accordion up to $18M.
XBP Europe stockholders approve 2024 equity plan, set exec compensation details
Plan authorizes up to 5,520,270 shares of common stock for equity awards.
XBP Europe Q1 revenue down 5.7% to $40.4M; net loss narrows; wins $40M HMPO contract
Revenue $40.4M (down 5.7% YoY); gross margin improved to 24.6% (+250 bps YoY).
XBP Europe receives Nasdaq deficiency notice for MVPHS below $15M
On April 19, 2024, Nasdaq notified XBP that MVPHS had been under $15M for 30 consecutive business days.
XBP Europe FY2023 revenue $166.6M, down 7.7%; net loss $11.0M; Adjusted EBITDA $11.6M
Revenue fell 7.7% YoY to $166.6M; Bills & Payments segment down 11%, Technology segment up 2.5%.
XBP Europe Holdings completes de-SPAC merger, begins trading under 'XBP' on Nasdaq
Business combination with XBP Europe closed Nov 29, 2023; common stock and warrants began trading on Nasdaq Nov 30 under XBP and XBPEW.
XBP Europe completes business combination with CF Acquisition Corp. VIII; begins trading on Nasdaq
Business combination closed on November 29, 2023; combined company renamed XBP Europe Holdings.
CF Acquisition Corp. VIII shareholders approve extension to Mar 2024; ~$8M redeemed
Extension deadline extended from Sep 16, 2023 to Mar 16, 2024 for business combination.
CF Acquisition Corp. VIII stockholders approve business combination with XBP Europe
Business Combination Proposal passed with 7,918,734 votes for, 100,614 against.
CF Acquisition Corp. VIII extends deadline to Sept 16, 2023; 51% of public shares redeemed
Shareholders approved extension to Sept 16, 2023; 8,804,026 for, 330,028 against.
Merger valued at $220M less XBP Europe's closing indebtedness; XBP Europe shareholders to receive shares of Class A common stock at $10.00 reference plus 1,330,650 shares.
CF Acquisition Corp. VIII extends deal deadline to Mar 16, 2023; $196M redeemed by stockholders
Stockholders approved extension of business combination deadline from Sep 30, 2022 to Mar 16, 2023.
CF Acquisition Corp. VIII restates financials; reclassifies all public shares as temporary equity
Audit Committee determined prior financial statements should no longer be relied upon.
Effective on September 1, 2023, Steven Bisgay resigned from the board of directors of CF Acquisition Corp. VIII, a Delaware corporation (the “Company”).
Effective March 16, 2022, the board of directors (the “ Board ”) of CF Acquisition Corp. VIII (the “ Company ”) appointed Mark Kaplan and Robert Sharp as members of the Board.
Effective March 16, 2022, the board of directors (the “ Board ”) of CF Acquisition Corp. VIII (the “ Company ”) appointed Mark Kaplan and Robert Sharp as members of the Board.
Ms. Chan resigned as Chief Financial Officer, director and member of the Audit Committee on July 5, 2021 in order to pursue other endeavors.
Additionally, the Board elected Steven Bisgay as a director and as a member of the audit committee of the Board (the “ Audit Committee ”).
Effective July 8, 2021, the board of directors (the “ Board ”) of CF Acquisition Corp. VIII (the “ Company ”) appointed Jane Novak as interim Chief Financial Officer of the Company.
Ms. Chan resigned as Chief Financial Officer, director and member of the Audit Committee on July 5, 2021 in order to pursue other endeavors.
Max materiality 1.00 · Median 0.70 · Most common event other_material